- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Treatment of uncomplicated malaria |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Children ≤ 12 years of age:
Very common (> 10%): headache, decreased appetite (both in about 17%). Cough (in ca. 23%). Vomiting (approx. 20%), abdominal pain.
Common (1-10%): dizziness. Palpitations, prolonged QT interval (ECG). Nausea, diarrhea. Sleep disturbances. Fatigue, asthenia. Muscle pain, joint pain. Skin rash. Increase in liver function values.
Uncommon (0.1-1%): clonus. Itching, urticaria.
Rare (0.01-0.1%): hypersensitivity reactions.
Further reported are: angioedema. Delayed hemolytic anemia (for several weeks after discontinuation of treatment).
Children > 12 years:
Very common (> 10%): headache, dizziness. Palpitations. Nausea, vomiting, abdominal pain. Fatigue, asthenia, decreased appetite. Muscle pain, joint pain.
Common (1-10%): paresthesia, clonus, gait disturbance. Insomnia. Cough. Diarrhea. Skin rash, itching. Prolonged QT interval (ECG).
Uncommon (0.1-1%): hypoaesthesia, ataxia. Drowsiness. Urticaria. Increased liver function values.
Further reported: hypersensitivity reactions, angioedema. Delayed hemolytic anemia (for several weeks after discontinuation of treatment).
[SmPC Riamet]
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Aminoquinolines | ||
|---|---|---|
| P01BA01 | ||
| P01BA02 | ||
| Biguanides | ||
|---|---|---|
| P01BB01 | ||
| Methanolquinolines | ||
|---|---|---|
| P01BC02 | ||
| P01BC01 | ||
| Diaminopyrimidines | ||
|---|---|---|
| P01BD01 | ||
| Artemisinin and derivatives, plain | ||
|---|---|---|
| P01BE03 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Novartis Pharma BV, SmPC Riamet (RVG 25773) 04-12-2020, www.geneesmiddeleninformatiebank.nl
- WHO, Guidelines for the treatment of malaria., www.who.int, 2015, 3rd edition
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
